IgGenix
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $40M
Overview
Engineers monoclonal antibodies from rare human immune cells to cure severe allergies and autoimmune disorders.
ImmunologyRare DiseaseAllergy
Technology Platform
A discovery platform that isolates and engineers high-affinity monoclonal antibodies from the B cells of individuals who have naturally overcome severe allergic diseases.
Funding History
1Total raised:$40M
Series B$40M
Opportunities
Potential to create the first curative or long-term therapeutic solutions for life-threatening food allergies, a multi-billion dollar unmet market.
Risk Factors
Clinical risk in translating natural immunity into a safe and effective therapeutic, and commercial challenges in allergy drug adoption and reimbursement.
Competitive Landscape
Competes with allergen immunotherapy and antibody companies in the allergy space, but its unique source of protective antibodies provides a distinct mechanism-of-action advantage.